June 29th 2025
Results from Invivyd’s pemivibart (Pemgarda) phase 3 trial show it had a significant PrEP effect during the 6-month on-drug period for both immunocompromised and immunocompetent populations.
June 25th 2025
New epidemiologic data, vaccine effectiveness, and safety assessments guide a move from universal to targeted vaccination recommendations for the 2025–26 season.
June 12th 2025
Although COVID-19 has receded quite a bit from the minds of many, it still remains a virus that can present serious morbidity and mortality. Here is a review of clinical treatment strategies by an intensivist when seeing patients with severe COVID-19.
June 12th 2025
Phase 3 results show immune response and tolerability in adults 65 and older, following phase 2 findings.
May 31st 2025
The company's vaccine, mRNA-1283, becomes the first approval under the new federal guidelines.
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
A Shield of Protection: Unmet Needs in COVID-19 Prevention and Control
October 7, 2025
Register Now!
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
The Tripledemic as a Precursor to Stakeholder Alignment under the Quintuple Aim
February 8th 2023Infectious disease outbreaks will continue to increase and trying to find strategies to ensure providers are cared for to prevent burnout and shortage staffing is essential if another pandemic arises.
Read More
As US COVID-19 Vaccine Policy Pivots, CDC Publishes Prevention Measures for Immunocompromised
January 29th 2023In the latest Morbidity and Mortality Weekly Report, authors offer some strategies to avoid SARS-CoV-2 infection in this patient population as well as the US government changes course on COVID-19 vaccine policy.
Read More
Large New Zealand Study Confirms Safety Profile of Pfizer-BioNTech Vaccine
January 26th 2023The Pfizer-BioNTech COVID-19 vaccine was associated with rare instances of myo/pericarditis and acute kidney injury, according to a nationwide study in New Zealand that confirmed the safety profile of the vaccine.
Read More
PREP Act Set to Sunset in 2024 Affecting Half of US States
January 18th 2023This act designed to allow pharmacists and technicians the ability to administer certain vaccines without a prescriber order will lapse next year. A new report looks at vaccination trends in the US and how pharmacists are playing a vital role in administering vaccines.
Read More
2 Commerce Drive
Cranbury, NJ 08512